Vivos Therapeutics, Inc.

NasdaqCM:VVOS Stock Report

Market Cap: US$16.3m

Vivos Therapeutics Past Earnings Performance

Past criteria checks 0/6

Vivos Therapeutics's earnings have been declining at an average annual rate of -2.2%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 3.3% per year.

Key information

-2.2%

Earnings growth rate

19.6%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate3.3%
Return on equity-164.0%
Net Margin-86.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

Revenue & Expenses Breakdown

How Vivos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:VVOS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2415-13210
30 Jun 2414-12210
31 Mar 2413-16230
31 Dec 2314-14250
30 Sep 2315-15270
30 Jun 2315-19290
31 Mar 2316-20320
31 Dec 2216-24340
30 Sep 2216-25360
30 Jun 2217-25360
31 Mar 2217-22340
31 Dec 2117-20310
30 Sep 2116-24270
30 Jun 2115-21230
31 Mar 2113-19200
31 Dec 2013-18180
30 Sep 2013-9180
30 Jun 2013-11190
31 Mar 2012-12190
31 Dec 1911-12180
31 Dec 184-9100

Quality Earnings: VVOS is currently unprofitable.

Growing Profit Margin: VVOS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VVOS is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare VVOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VVOS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).


Return on Equity

High ROE: VVOS has a negative Return on Equity (-163.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies